Celator

Celator Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to developing therapies for the treatment of cancer. The company focuses on CombiPlex, a drug ratio technology platform that can be used to develop combination therapies. Its products include CPX-1 (Irinotecan HCl-Floxuridine), for the treatment of colorectal cancer, and CPX-351 (Cytarabine-Daunorubicin), for the treatment of acute myeloid leukemia (AML). Celator Pharmaceuticals, Inc. was previously known as Celator Technologies, Inc. The company was founded in 2000 and is headquartered in Princeton, New Jersey.